Subscribe To
ZBH / J&J Medtech Outlook Boosts Shares of Stryker, Biomet and Intuitive
ZBH News
By Zacks Investment Research
October 31, 2023
Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key e more_horizontal
By Zacks Investment Research
October 30, 2023
Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?
Zimmer Biomet (ZBH) is expected to have witnessed strong performance across Avenir Complete hip. more_horizontal
By Zacks Investment Research
September 29, 2023
Here's Why You Should Retain Zimmer Biomet (ZBH) for Now
Investors are optimistic about Zimmer Biomet (ZBH) on business recovery and expansion in emerging markets. more_horizontal
By Zacks Investment Research
September 29, 2023
Zimmer Biomet (ZBH) Gains From ROSA Sales Growth Amid FX Woes
Zimmer Biomet (ZBH) plans to work on the overall shift of the company's legacy knee systems to a fully rounded-out Persona portfolio. more_horizontal
By Seeking Alpha
September 14, 2023
Zimmer Biomet Holdings: Growth Strategies For 2023 Instill Confidence
Zimmer Biomet Holdings outlined strategies to gain market share in the knee sector and foster innovation in hip products. ZBH has raised its 2023 grow more_horizontal
By Zacks Investment Research
September 5, 2023
Zimmer Biomet (ZBH) Business Recovery Continues Despite FX Woe
Zimmer Biomet (ZBH) is benefiting from increased provider capacity, resulting in backlog pull-through in the recent quarters. more_horizontal
By Zacks Investment Research
August 30, 2023
Here's Why You Should Retain Zimmer Biomet (ZBH) for Now
Investors are optimistic about Zimmer Biomet (ZBH) due to innovative new product launches and solid execution. more_horizontal
By Seeking Alpha
August 12, 2023
Zimmer Biomet: Knees The Key Growth Lever, Reiterate Buy On Long-Term Value
Zimmer Biomet Holdings, Inc. has experienced a selloff alongside the healthcare sector in H2 FY'23. Despite the recent downturn, the company still rep more_horizontal